Year Founded
2018
Ownership
Public
Employees
~100
Stage
Phase 1
Modalities
Autologous cell therapyT cell receptor therapy (TCR-T)

Neogene Therapeutics General Information

Clinical-stage biotech developing TCR-T cell therapies targeting neoantigens in solid cancers. Acquired by AstraZeneca for $320M.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Amsterdam,
Netherlands

Drug Pipeline

No pipeline data available

For full access to Neogene Therapeutics's pipeline data

Book a demo

Key Partnerships

AstraZeneca

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Neogene Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Neogene Therapeutics's complete valuation and funding history, request access »

Neogene Therapeutics Investors

Vida Ventures
Investor Type: Venture Capital
Holding: Minority
TPG
Investor Type: Venture Capital
Holding: Minority
EcoR1 Capital
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 7 investors. Get the full list »